EvolutionaryScale, a US AI startup, recently secured $142 million in seed funding to develop AI technology capable of generating new proteins for various scientific and medical applications. The funding will enhance the company’s collaboration with the biotech industry. EvolutionaryScale, founded in 2023, is supported by major companies like Amazon Web Services (AWS) and NVIDIA.
The startup introduced its latest product, ESM3, an artificial general intelligence model that can produce new proteins. This innovation significantly accelerates the process of protein evolution, which may have naturally taken 500 million years. EvolutionaryScale envisions a future where AI plays a pivotal role in the field of biology.
The company’s partnership with AWS and NVIDIA ensures widespread accessibility of the ESM3 model for researchers globally, including the top pharmaceutical companies. This new AI model has diverse applications, from advancing cancer treatments to promoting carbon capture. Global data projects significant growth in the global AI market within the medical device industry, with an anticipated CAGR of 29.1% from 2023 to 2027.
EvolutionaryScale’s groundbreaking technology has the potential to revolutionize protein development and enhance various scientific and medical research initiatives. The company’s focus on innovation and collaboration with industry leaders positions it as a frontrunner in the field of AI-driven protein generation. With the support of AWS and NVIDIA, EvolutionaryScale is poised to make significant contributions to the advancement of AI in biology and beyond.
Article Source
https://www.verdict.co.uk/news/amazon-and-nvidia-backed-startup-evolutionaryscale-raises-142m-to-advance-protein-g/